Table 2 Cough details, and other therapies, including cancer-directed therapy in patients with lung cancer and chronic cough, treated with pregabalin or placebo as part of the cough study
From: Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial
Cough and therapy details | All patients, in number (%) (n = 166) | Pregabalin arm, in number (%) (n = 83) | Placebo arm, in number (%) (n = 83) | P-value |
|---|---|---|---|---|
Cough symptom relief on day 7 | ||||
Yes | 118 (71.1) | 56 (67.5) | 62 (74.7) | 0.191 |
No | 35 (21.1) | 22 (26.5) | 13 (15.7) | |
Cough relief in % on day 7, in median (IQR) | 20 (0–50) | 10 (0–50) | 20 (10–50) | 0.431 |
Cough grade on day 7 | ||||
No cough | 2 (1.3) | 2 (2.5) | 0 | 0.552 |
Grade 1 | 77 (48.1) | 39 (48.1) | 38 (48.1) | |
Grade 2 | 72 (45.0) | 36 (44.4) | 36 (45.6) | |
Grade 3 | 9 (5.6) | 4 (4.9) | 5 (6.3) | |
Not assessed | ||||
Cough symptom relief at week 9 | ||||
Yes | 92 (55.4) | 50 (66.2) | 42 (50.6) | 0.230 |
No | 8 (4.8) | 2 (2.4) | 6 (7.2) | |
Cough relief in % at week 9, in median (IQR) | 80 (50–100) | 80 (50–100) | 70 (23.5–92.5) | 0.182 |
Cough grade at week 9 | ||||
No cough | 33 (19.9) | 20 (24.1) | 13 (15.7) | 0.129 |
Grade 1 | 79 (47.6) | 42 (50.6) | 37 (44.6) | |
Grade 2 | 10 (6.0) | 6 (7.2) | 4 (4.8) | |
Grade 3 | 1 (0.6) | 1 (1.2) | 0 | |
Not assessed | 43 (25.9) | 15 (18.1) | 28 (33.7) | |
Requirement for additional medicines for cough while on study | ||||
No | 84 (50.6) | 45 (54.2) | 39 (47.0) | 0.362 |
Yes | 81 (48.8) | 37 (44.6) | 44 (53.0) | |
Additional medicines while on study | ||||
Inhalers | 34 (34.5) | 17 (34.5) | 17 (34.4) | 0.622 |
Steroids | 37 (22.9) | 21 (25.3) | 17 (20.5) | 0.465 |
Morphine | 32 (19.3) | 15 (18.1) | 17 (20.5) | 0.694 |
Etoricoxib | 7 (4.2) | 4 (4.8) | 3 (3.6) | 1.00 |
Tramadol | 81 (48.8) | 40 (48.2) | 41 (49.4) | 0.877 |
Antibiotics | 70 (42.2) | 36 (43.3) | 34 (41.0) | 0.535 |
